Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...
New York Post on MSN13d
FDA greenlights GSK’s drug for UTIs in women and girlsREUTERS/Chris J. Ratcliffe/File Photo GSK is banking on new drugs in its infectious diseases portfolio, including its ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, ...
(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...
April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory ...
GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, Abrysvo for respiratory syncytial virus (RSV) allegedly violated the British pharma giant’s patent rights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback